Silo Pharma (SILO) announced completion of dosing in a U.S. Food and Drug Administration-requested 7-day safety and toxicology large animal study of its lead asset SPC-15, and bioanalytical and safety/toxicology results for such study are expected within 60 days. Two remaining SPC-15 studies are currently in progress or being planned: an IND-enabling GLP-compliant toxicology and toxicokinetic animal study, and a device study of SPC-15’s formulation-specific microchip-based nasal spray system. Silo plans to seek the FDA’s 505(b)(2) regulatory pathway for approval of SPC-15, a drug development route that can significantly shorten clinical timelines for FDA approval and reduce drug development costs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SILO:
- Silo Pharma Secures Exclusive License for CNS Peptides
- Silo Pharma expects preclinical study data on SPC-15 in Q3
- Silo Pharma Faces Nasdaq Non-Compliance Notice
- Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial
- Silo Pharma enters into letter of intent to form 50:50 joint venture with Hoth